Reports Of Delay In Licensing For Covaxin Factually Incorrect : Centre Reports Of Delay In Licensing For Covaxin Factually Incorrect : Centre The Union government is consistently and pro-actively working to secure and enhance the availability of vaccines, the Health Ministry said.
Covaxin is manufactured by the Hyderabad-based Bharat Biotech. (File)
New Delhi:
The government on Thursday dismissed as completely baseless and factually incorrect reports in a section of media followed by some tweets alleging delay in licensing for Covaxin and delayed approval for technology transfer for manufacturing the vaccine in the country.
The Union government is consistently and pro-actively working to secure and enhance the availability of vaccines, the Health Ministry said, adding that Government of India is pro-actively engaging with foreign vaccine manufacturers like Moderna, Pfizer to apply for emergency use authorisation in India so that these vaccines can be easily importe
Covaxin has been developed by Hyderabad-based Bharat Biotech.
New Delhi:
Bharat Biotech s COVID-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase-2 and phase-3 clinical trials on those aged between two to 18 years, official sources said.
The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.
The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) on Tuesday deliberated upon Hyderabad-based Bharat Biotech s application, seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years.
Updated May 11, 2021 · 05:38 pm
Maharashtra Health Minister Rajesh Tope on Tuesday said the government will have to temporarily halt the vaccination drive for the 18 to 45 age group because of vaccine shortages, even as the country faces its worst surge in infections since the beginning of the pandemic, NDTV reported.
“We are slowing down the process for 18-44 [year olds] because we don’t have vaccines,” Tope told the channel. “We don’t want to stop, but right now we have no vaccines, so we will be giving vaccines right now to 45 plus only.”
The health minister added that Maharashtra had set aside about 2.75 lakh doses for inoculating adults, which would now be used for those above 45 who are yet to receive their second dose, according to ANI. “Administering the second dose is priority,” he said.
May 04, 2021
×
A previous study had suggested that this vaccine was effective against the UK variant and Indian double mutant variant
In a new study, scientists at Indian Council of Medical Research (ICMR)-National Institute of Virology have found that Covaxin demonstrated potential effectiveness against the Brazil variant of SARS-CoV-2.
This was announced by Biopharmaceuitcal company, Ocugen, Inc.
Ocugen is developing Hyderabad-based Bharat Biotech`s Covaxin for the US market. As previously disclosed, a study conducted by ICMR also suggested that Covaxin was effective against the UK variant, as well as the Indian double mutant variant, Ocugen said in a release
Bengaluru, April 28 : Karnataka on Wednesday placed an order to buy 1 crore doses of anti-Covid vaccines to inoculate adults in the 18-44 years age group